Publication
Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (4)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 4
- cancerGastrointestinal Stromal Tumorcivic_curation1.00
- geneKITcivic_curation1.00
- variantKIT Exon 11 Mutationcivic_curation1.00
- variantKIT Exon 14 Mutationcivic_curation1.00
Curated evidence
Evidence citing this paper (5)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 16551858
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| KIT Exon 11 Mutation1 | ||||||||
| (prognostic) | Gastrointestinal Stromal Tumor | Prognostic | B | Does Not Support N/A | 3 | accepted | EID53There is no significant association between wildtype KIT or KIT mutations in exon 9 or 11 in survival among GIST patients. PMID 16551858 · Wardelmann et al., 2006 · Open in CIViC | civic |
| KIT Exon 14 Mutation1 | ||||||||
| (prognostic) | Gastrointestinal Stromal Tumor | Prognostic | B | Supports Poor Outcome | 3 | accepted | EID70GIST patients with exon 14 KIT mutations had reduced overall survival compared to patients wiltype for KIT. PMID 16551858 · Wardelmann et al., 2006 · Open in CIViC | civic |
| KIT EXPRESSION1 | ||||||||
| Imatinib | Gastrointestinal Stromal Tumor | Predictive | B | Supports Resistance | — | submitted | EID2488Primary KIT mutations are detected in 75-80% of GIST patients, and primarily occur in exons 9 and 11, wheareas secondary KIT mutations associated with resistance to imatinib are found in exons 13,14, … (full text at CIViC) PMID 16551858 · Wardelmann et al., 2006 · Open in CIViC | civic |
| KIT Q694K1 | ||||||||
| Imatinib | Gastrointestinal Stromal Tumor | Predictive | B | Supports Resistance | — | submitted | EID2498Primary KIT mutations are detected in 75-80% of GIST patients, and primarily occur in exons 9 and 11, wheareas secondary KIT mutations associated with resistance to imatinib are found in exons 13,14, … (full text at CIViC) PMID 16551858 · Wardelmann et al., 2006 · Open in CIViC | civic |
| KIT S692L1 | ||||||||
| Imatinib | Gastrointestinal Stromal Tumor | Predictive | B | Supports Resistance | — | submitted | EID2493Primary KIT mutations are detected in 75-80% of GIST patients, and primarily occur in exons 9 and 11, wheareas secondary KIT mutations associated with resistance to imatinib are found in exons 13,14, … (full text at CIViC) PMID 16551858 · Wardelmann et al., 2006 · Open in CIViC | civic |